Search
Regulatory Story
Company GlaxoSmithKline PLC
TIDM GSK
Headline Director/PDMR Shareholding
Released 17:35 16-Apr-2019
Number 4072W17

RNS Number : 4072W
GlaxoSmithKline PLC
16 April 2019
 

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

 

a)

Name

Ms E Walmsley

 

b)

Position/status

Chief Executive Officer

 

c)

Initial notification/

amendment

Initial notification

 

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

GlaxoSmithKline plc

 

b)

LEI

5493000HZTVUYLO1D793

 

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

 

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

 

b)

Nature of the transaction

Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.6560

908.000

£15.6560

260.000

£15.6560

912.000

£15.6560

260.000

 

 

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

2340.000 

£15.6560

 

 

e)

Date of the transaction

2019-04-12
 

 

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

     

 

1.

Details of PDMR/person closely associated with them ('PCA')

 

a)

Name

Dr H Barron

 

b)

Position/status

Chief Scientific Officer and President, R&D

 

c)

Initial notification/

amendment

Initial notification

 

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

GlaxoSmithKline plc

 

b)

LEI

5493000HZTVUYLO1D793

 

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

 

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053 

 

 

b)

Nature of the transaction

Increase in interest in American Depository Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on American Depository Shares held in the Company's Deferred Annual Bonus Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$ 40.9400

538.000

 

 

 

 

d)

Aggregated information

Aggregated volume Price

 

n/a (single transaction)

 

 

 

 

 

e)

Date of the transaction

2019-04-12

 

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

             

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.6560

238.000

£15.6560

135.000

£15.6560

193.000

£15.6560

135.000

 

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

701.000 

£15.6560

  

e)

Date of the transaction

2019-04-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S P Dingemans

b)

Position/status

Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

b)

Nature of the transaction

Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.6560

649.000

£15.6560

236.000

£15.6560

645.000

£15.6560

236.000

 

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

1766.000 

£15.6560

 

e)

Date of the transaction

2019-04-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr J Ford

b)

Position/status

SVP and General Counsel

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053 

 

b)

Nature of the transaction

Increase in interest in American Depository Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on American Depository Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$ 40.9400

46.000

  

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

e)

Date of the transaction

2019-04-12

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.6560

99.000

£15.6560

85.000

£15.6560

101.000

£15.6560

85.000

 

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

370.000 

£15.6560

 

e)

Date of the transaction

2019-04-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, GSK Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053 

 

b)

Nature of the transaction

Increase in interest in American Depository Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on American Depository Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$ 40.9400

90.000

$ 40.9400

98.000

$ 40.9400

96.000

 

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 


284.000 

$ 40.9400

e)

Date of the transaction

2019-04-12

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Miels

b)

Position/status

President, Global Pharmaceuticals

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.6560

253.000

£15.6560

183.000

 

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

436.000
£15.6560

 

e)

Date of the transaction

2019-04-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.6560

225.000

£15.6560

107.000

£15.6560

187.000

£15.6560

107.000

  

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

626.000 

£15.6560

 

e)

Date of the transaction

2019-04-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Simard

b)

Position/status

President, Pharmaceuticals Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.6560

81.000

 

 

 

d)

Aggregated information

 

Aggregated volume Price

 

n/a (single transaction)

 

 

 

e)

Date of the transaction

2019-04-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

  

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms K Terrell

b)

Position/status

Chief Digital & Technology Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053 

 

b)

Nature of the transaction

Increase in interest in American Depository Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on American Depository Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$ 40.9400

114.000

$ 40.9400

32.000

 

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

146.000

$ 40.9400

  

e)

Date of the transaction

2019-04-12

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.6560

131.000

£15.6560

102.000

£15.6560

126.000

 

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

359.000 

£15.6560

 

e)

Date of the transaction

2019-04-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHQQLFFKZFXBBX
London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.